Moreover, ralimetinib showed a synthetic lethality effect when used in combination with the MEK1 inhibitor trametinib in patient-derived CRC-SC tumorspheres, in a human 3D culture system, and in APCMin/+ mice organoids. Here, MAP2K1 is linked to colorectal carcinoma.